STOCK TITAN

Masimo Corporation - MASI STOCK NEWS

Welcome to our dedicated page for Masimo Corporation news (Ticker: MASI), a resource for investors and traders seeking the latest updates and insights on Masimo Corporation stock.

Masimo Corporation (NASDAQ: MASI) is a leading global medical technology company specializing in the development and manufacturing of innovative noninvasive patient monitoring technologies. For over 27 years, Masimo has been at the forefront of medical advancements, offering a wide array of sensors and devices that enhance patient care and safety. Their products are designed to provide healthcare professionals with critical information to improve clinical decision-making.

Masimo's core business is divided into two segments: healthcare and non-healthcare. The healthcare segment is the primary revenue generator, focusing on noninvasive patient monitoring technologies, hospital automation, connectivity solutions, and remote monitoring devices. Their clinically proven products are widely used in hospitals, emergency rooms, and clinical settings around the world.

The non-healthcare segment encompasses the consumer audio business, which includes the development, manufacturing, marketing, and licensing of premium and luxury audio sound products. This segment is known for its advanced audio integration technologies that appeal to audiophiles and general consumers alike.

Masimo's recent achievements include expanding their product portfolio with advanced remote monitoring solutions, partnering with leading healthcare organizations, and pioneering innovative technologies that address unsolvable medical challenges. Financially, the company is robust, showing consistent growth and a strong market presence.

Masimo’s dedication to improving lives is evident in their mission to save, extend, and enhance the quality of life across all demographics. Their innovative spirit attracts individuals who are passionate about making a significant impact in the medical field. As they continue to innovate, Masimo remains committed to providing top-tier products that meet the evolving needs of the healthcare industry.

Rhea-AI Summary

Masimo (NASDAQ: MASI) announced the results of a study published in Clinical Medicine Insights: Pediatrics, showing the effectiveness of its Rad-G® Pulse Oximeter in detecting pneumonia in over 4,500 children under five in India. The study indicated that Rad-G helped achieve over 91% accurate case management of acute respiratory infections, reducing unnecessary antibiotic use. Researchers noted that Rad-G's usability and reliability make it suitable for low-resource settings, potentially transforming pneumonia diagnosis. The study highlights the critical need for improved pneumonia management tools in India, where pneumonia contributes to significant child mortality.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.46%
Tags
none
-
Rhea-AI Summary

MDoloris Medical Systems has received regulatory clearance and marketing approval for its HFVI MOC-9 monitor in Japan. This innovation is the first of its kind for monitoring patients under analgosedation and anesthesia in Japan, integrating with Masimo's Root patient monitoring hub. The HFVI MOC-9 improves assessment of parasympathetic activity during surgeries, enhancing postoperative outcomes and reducing opioid use. Heiwa Bussan will exclusively market this technology in Japan, indicating strong sales potential in a significant market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Masimo (NASDAQ: MASI) is set to participate in the Piper Sandler 33rd Annual Healthcare Conference on November 30, 2021, at 2:00 p.m. Eastern Time. The event will feature a live webcast available on the Masimo website, with a replay option for later viewing. Masimo is recognized for its advanced medical monitoring technologies and aims to enhance patient care while reducing associated costs. Its pulse oximetry technology is utilized in top hospitals globally, proving a significant impact on patient outcomes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.19%
Tags
conferences
Rhea-AI Summary

Masimo (NASDAQ: MASI) released findings from a study published in Frontiers in Neurology demonstrating that its SedLine® Brain Function Monitoring can significantly reduce the incidence of postoperative delirium (POD) in carotid endarterectomy patients. In a trial with 255 participants, those monitored with SedLine exhibited a 7.87% POD rate compared to 28.91% for standard monitoring (p < 0.01). The study highlights the potential for improved patient outcomes through enhanced anesthesia management using multiple EEG parameters.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.36%
Tags
none
-
Rhea-AI Summary

Masimo (NASDAQ: MASI) will participate in the Stifel 2021 Virtual Healthcare Conference on November 16, 2021, at 4:00 p.m. Eastern Time. A live webcast can be accessed via the Masimo website, with a replay available post-event. Masimo is known for its innovative medical technologies including pulse oximetry that enhances patient monitoring. Established in 1995, their SET® technology is used globally, improving outcomes and reducing healthcare costs. For more details, visit www.masimo.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.77%
Tags
conferences
-
Rhea-AI Summary

Masimo (NASDAQ: MASI) announced a study published in Frontiers in Aging Neuroscience indicating that its Root® monitoring platform could enhance postoperative cognitive function in elderly patients undergoing spinal surgery. The study involved 26 patients, showing that the intervention group managed with a multimodal algorithm had a higher mean postoperative MoCA score (24.80) compared to the control group (22.56). The research suggests that the algorithm's precision in monitoring could reduce the risk of postoperative neurocognitive disorder.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.56%
Tags
none
Rhea-AI Summary

Masimo (NASDAQ: MASI) has launched Dual SET® Pulse Oximetry for Root®, enhancing critical congenital heart disease (CCHD) screening. The CE-marked Masimo SET® MOC-9® module and the Eve™ application enable simultaneous pre- and post-ductal oxygen saturation measurements, improving newborn screening efficiency. CCHD affects 2.5 to 3 newborns per 1,000 births, necessitating early detection to reduce mortality and morbidity. Masimo's technology has shown increased screening sensitivity, enhancing newborn care and clinical workflows, although the new products are not yet FDA cleared for the U.S.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.12%
Tags
none
-
Rhea-AI Summary

Masimo (NASDAQ: MASI) reported Q3 2021 financial results, highlighting product revenue of $307.4 million, a growth of 10.5% from Q3 2020. GAAP net income reached $57.8 million, or $1.00 per diluted share, up from $49.4 million, or $0.85 per share in the previous year. The company maintained strong operational performance with GAAP operating margins of 22.0% and non-GAAP margins at 23.0%. For full-year 2021, Masimo revised its guidance to a total revenue of $1.230 billion, representing a projected growth of 7.5%.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.12%
Tags
-
Rhea-AI Summary

Masimo (NASDAQ: MASI) presented findings at ANESTHESIOLOGY 2021, demonstrating the efficacy of its PVi® technology in managing fluid administration during major oncosurgery. Researchers from Rajiv Gandhi Cancer Institute found that patients guided by PVi received significantly less fluid and exhibited fewer B-lines, indicators of extravascular lung water (EVLW), without a decrease in postoperative oxygenation compared to those using conventional CVP methods. These results highlight PVi's potential for enhanced patient care in surgical settings.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.02%
Tags
none
Rhea-AI Summary

Masimo (NASDAQ: MASI) will announce its third quarter 2021 financial results on October 26, 2021, after market close. The results will be discussed in a conference call scheduled for 1:30 p.m. PT (4:30 p.m. ET), featuring CEO Joe Kiani and CFO Micah Young. Masimo is a renowned medical technology company focused on noninvasive monitoring technologies aimed at improving patient outcomes and reducing costs. The company’s drive for innovation has made its technologies integral in leading hospitals globally.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.82%
Tags
conferences earnings

FAQ

What is the current stock price of Masimo Corporation (MASI)?

The current stock price of Masimo Corporation (MASI) is $160.15 as of November 14, 2024.

What is the market cap of Masimo Corporation (MASI)?

The market cap of Masimo Corporation (MASI) is approximately 8.5B.

What is Masimo Corporation's main business?

Masimo Corporation specializes in developing and manufacturing noninvasive patient monitoring technologies and premium audio products.

How long has Masimo Corporation been in operation?

Masimo has been operational for over 27 years, continually innovating in the medical technology field.

What are the key segments of Masimo's business?

Masimo operates in two key segments: healthcare, which includes patient monitoring technologies, and non-healthcare, which includes premium audio products.

What products does Masimo offer?

Masimo offers noninvasive patient monitoring devices, sensors, remote monitoring solutions, hospital automation products, and luxury audio sound systems.

What makes Masimo's products unique?

Masimo's products are known for their innovative, noninvasive technology that provides accurate patient monitoring and critical information for clinical decision-making.

Who uses Masimo's healthcare products?

Masimo's healthcare products are used by healthcare professionals in hospitals, clinics, emergency rooms, and other medical settings.

What recent achievements has Masimo Corporation accomplished?

Masimo has expanded their product portfolio with advanced remote monitoring solutions and established partnerships with leading healthcare organizations.

What is the financial status of Masimo Corporation?

Masimo Corporation has shown consistent financial growth and maintains a strong market presence.

What is Masimo's mission?

Masimo's mission is to save, extend, and improve lives by developing innovative medical technologies and solutions.

Where can I find the latest news about Masimo Corporation?

The latest news about Masimo Corporation can be found on their official website and trusted financial news sources.

Masimo Corporation

Nasdaq:MASI

MASI Rankings

MASI Stock Data

8.53B
53.18M
8.15%
91.14%
6.7%
Medical Devices
Electromedical & Electrotherapeutic Apparatus
Link
United States of America
IRVINE